Promising Results for Pembrolizumab With Bevacizumab in mRCC

Shilpa Gupta, MD

Shilpa Gupta, MD, assistant professor of Medicine in the Hematology, Oncology, and Transplantation Division, University of Minnesota, discusses phase Ib and phase II studies of pembrolizumab (Keytruda) with bevacizumab (Avastin) for the treatment of metastatic renal cell carcinoma during the 2018 ASCO Annual Meeting.

Shilpa Gupta, MD, assistant professor of Medicine in the Hematology, Oncology, and Transplantation Division, University of Minnesota, discusses phase Ib and phase II studies of pembrolizumab (Keytruda) with bevacizumab (Avastin) for the treatment of metastatic renal cell carcinoma (mRCC) during the 2018 ASCO Annual Meeting.